Who is the CEO of Q-Line Biotech Ltd?
- Answer Field
-
Ajay Kumar Mahanty is the CEO and Saurabh Garg is the Chairman and Managing Director of Q-Line Biotech Ltd.
Q-Line Biotech Ltd. operates in the in-vitro diagnostics (IVD) segment and is engaged in the manufacturing and supply of diagnostic reagents, consumables, and healthcare diagnostic equipment. The Q-Line Biotech IPO is scheduled to open on May 21, 2026, and close on May 25, 2026. The IPO consists of 62,53,200 equity shares with a price band of ₹326 to ₹343 per share. The company plans to utilise the proceeds towards working capital requirements, repayment of certain borrowings, and general corporate purposes. The shares are proposed to be listed on the SME platform of NSE.
Q-Line Biotech Ltd. operates in the in-vitro diagnostics (IVD) segment and is engaged in the development, manufacturing, marketing, import, and distribution of diagnostic reagents, consumables, and healthcare diagnostic equipment. The company supplies products to hospitals, diagnostic laboratories, medical colleges, and healthcare service providers through direct channels and distributor networks. Its business operations include segments such as clinical chemistry, haematology, immunodiagnostics, molecular diagnostics, and point-of-care diagnostic solutions. Its operations are supported by manufacturing facilities involved in the production of diagnostic kits and reagents across multiple categories. The company’s product portfolio and supply network have contributed to its presence within the healthcare diagnostics market. Q-Line Biotech Ltd. continues to operate in a sector influenced by increasing healthcare awareness, diagnostic testing requirements, and the adoption of preventive healthcare practices across India.
Investors can apply for the Q-Line Biotech Ltd IPO through the ASBA (Application Supported by Blocked Amount) process available via net banking platforms offered by authorised banks. Applicants are required to log in to their banking portal, select the IPO section, choose the Q-Line Biotech Ltd IPO, enter the bid quantity and price within the specified price band, and submit the application using their PAN details and demat account information. The application amount remains blocked in the bank account until the allotment process is completed. Applications can also be submitted through UPI-supported IPO platforms provided by registered stockbrokers and trading applications. Investors need to select the IPO, enter bidding details, provide their UPI ID, and approve the mandate request through the UPI application before the specified deadline. Investors are required to ensure that their demat account, PAN details, and bank account information are updated and linked correctly before applying for the IPO.
For more details, visit the Q-Line Biotech IPO page.
Details | Information |
IPO Date | May 21, 2026 to May 25, 2026 |
Issue Size | 62,53,200 shares (agg. up to ₹214.48 Cr) |
Price Band | ₹326 to ₹343 per share |
Lot Size | 400 shares |
Listing At | SME, NSE |
Market Maker | Hem Finlease Pvt. Ltd. |
To meet working capital requirements
Repayment of certain borrowing availed by the company, in part or full
General corporate purposes
Event | Date |
|---|---|
IPO Open Date | Thu, May 21, 2026 |
IPO Close Date | Mon, May 25, 2026 |
Tentative Allotment | Tue, May 26, 2026 |
Initiation of Refunds | Wed, May 27, 2026 |
Credit of Shares to Demat | Wed, May 27, 2026 |
Tentative Listing Date | Fri, May 29, 2026 |
Cut-off time for UPI mandate confirmation | 5 PM on Mon, May 25, 2026 |
₹326 to ₹343 per share
Application | Lots | Shares | Amount |
Individual investors (Retail) (Min) | 2 | 800 | ₹2,74,400 |
Individual investors (Retail) (Max) | 2 | 800 | ₹2,74,400 |
S-HNI (Min) | 3 | 1,200 | ₹4,11,600 |
S-HNI (Max) | 7 | 2,800 | ₹9,60,400 |
B-HNI (Min) | 8 | 3,200 | ₹10,97,600 |
The Q-Line Biotech IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:
Access your trading account using the trading platform.
Go to the IPO section to view active IPO listings.
Locate Q-Line Biotech IPO in the list of available IPOs and click the ‘Apply’ button.
Specify the number of shares (lot size: 400 shares) within the price band of ₹326 to ₹343 per share.
Enter your UPI ID for payment authorisation and ensure sufficient funds in your bank account.
Review your application details and confirm the UPI mandate before 5 PM on the last application day.
Submit the application and monitor the allotment status to check if shares have been allocated to you.
The allocation of shares in the Q-Line Biotech IPO is structured across investor categories in line with applicable regulatory requirements. The issue provides defined reservations for qualified institutional buyers, non-institutional investors, and retail individual investors, with each category allotted a specified proportion of the net issue. This allocation framework outlines how the shares offered are distributed among different classes of investors.
Investor Category | Shares Offered | % of Net Issue | % of Total Issue |
QIB Shares Offered | 29,69,200 | 49.99% | 47.48% |
– Anchor Investor Shares Offered | 17,81,200 | — | 28.48% |
– QIB (Ex. Anchor) Shares Offered | 11,88,000 | — | 19.00% |
NII (HNI) Shares Offered | 8,91,600 | 15.01% | 14.26% |
Retail Shares Offered | 20,79,200 | 35.00% | 33.25% |
Firm Reservations | |||
Market Maker Shares Offered | 3,13,200 | — | 5.01% |
Total Shares Offered | 62,53,200 | 100.00% | 100.00% |
This reservation structure reflects the categorisation and allocation approach disclosed for the issue, indicating the proportion of shares available to each investor segment.
Total Assets: Grew from ₹251.58 crore in FY23 to ₹455.49 crore as of March 2025.
Total Income: Recorded at ₹322.58 crore in March 2025, as compared to ₹184.81 crore in FY23.
Profit After Tax (PAT): Reported at ₹28.13 crore in March 2025, and ₹32.10 crore in FY23.
Net Worth: Recorded at ₹189.95 crore in March 2025 compared to ₹127.37 crore in FY23.
Reserves & Surplus: Stood at ₹188.37 crore in March 2025, as compared to ₹125.79 crore in FY23.
Total Borrowings: Stood at ₹164.95 crore in March 2025, as compared to ₹73.65 crore in FY23.
EBITDA: Stood at ₹71.32 crore in March 2025 in comparison to ₹32.98 crore in FY23.
The company reported growth in its asset base, reflecting expansion in operational scale and business activities over the reviewed period.
Revenue generation showed an upward trend, supported by increased business operations within the diagnostics and healthcare segment.
Operating performance improved during the period, indicating changes in business efficiency and operational activities.
The company also reported growth in net worth and reserves, which reflects changes in its overall financial position.
Borrowings increased during the period, highlighting a higher reliance on external funding for operational or expansion-related requirements.
Profitability remained subject to fluctuations despite growth across several financial and operational areas.
The company reported an increase in total borrowings over the reviewed period, which may lead to higher financial obligations and repayment-related commitments.
Profit after tax reflected fluctuations despite growth in revenue, assets, and operational performance, indicating variations in overall profitability during the period under review.
The company operates in the in-vitro diagnostics and healthcare diagnostics segment, which continues to witness demand supported by diagnostic testing requirements and preventive healthcare awareness in India.
Growth in total income, operational performance, asset base, net worth, and reserves reflects expansion in business activities, manufacturing operations, and distribution capabilities across its product segments.
KPI | Dec 31, 2025 | Mar 31, 2025 |
ROE | 16.88% | 17.66% |
ROCE | 13.32% | 23.74% |
Debt/Equity | 1.06 | 0.87 |
RoNW | 16.88% | 23.74% |
PAT Margin | 16.65% | 8.97% |
EBITDA Margin | 27.64% | 22.73% |
Registrar | Lead Manager(s) |
|---|---|
Purva Sharegistry (India) Pvt. Ltd. | Hem Securities Ltd., Share India Capital Services Pvt. Ltd. |
298-281,
Transport Nagar,
Kanpur Road, Adjacent Transport Nagar Metro Station,
Lucknow, Uttar Pradesh, 226012
Phone: +91 522-2435570
Email: compliance@qlinebiotech.com
Website: https://qlinebiotech.com/
Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Q-Line Biotech IPO allotment status.
Ajay Kumar Mahanty is the CEO and Saurabh Garg is the Chairman and Managing Director of Q-Line Biotech Ltd.
The Q-Line Biotech IPO is scheduled to open for subscription on May 21, 2026, and close on May 25, 2026. The tentative allotment date is May 26, 2026, while the tentative listing date is May 29, 2026 on the NSE SME platform.
Q-Line Biotech Ltd. operates in the in-vitro diagnostics (IVD) segment and is engaged in the development, manufacturing, marketing, import, and distribution of diagnostic reagents, consumables, and healthcare diagnostic equipment. Its product categories include clinical chemistry, haematology, immunodiagnostics, molecular diagnostics, and point-of-care devices. The company supplies products to hospitals, diagnostic laboratories, and medical institutions through direct channels and distributors. The sustainability of the business model may depend on factors such as demand for diagnostic testing, healthcare infrastructure development, operational efficiency, regulatory compliance, and market conditions within the healthcare diagnostics sector.
The Q-Line Biotech IPO consists of 62,53,200 equity shares aggregating up to ₹214.48 crore.
The ‘pre-apply’ facility allows investors to submit their IPO application details before the issue officially opens for subscription. The application remains pending until the IPO opening date, after which the UPI mandate request is generated for approval. The process helps investors prepare their application in advance within the permitted IPO timeline.
The lot size for the Q-Line Biotech IPO is 400 shares. Retail investors are required to apply for a minimum of two lots, which equals 800 shares. Based on the upper price band, the minimum retail application amount is ₹2,74,400.
The tentative allotment date for the Q-Line Biotech IPO is May 26, 2026. Investors can check the allotment status after the basis of allotment is finalised by the registrar.
Purva Sharegistry (India) Pvt. Ltd. has been appointed as the registrar for the Q-Line Biotech IPO. The registrar is responsible for processing IPO applications, allotment-related activities, and investor-related queries associated with the issue..
There are no publicly stated governance issues or red flags highlighted. Investors may review the offer documents, including sections on management, board composition, and risk factors, for detailed and verified disclosures.
Investors can apply for the Q-Line Biotech IPO through the ASBA facility available via authorised banking platforms or through UPI-supported trading applications. Applicants are required to log in to their trading or banking platform, select the IPO section, enter the bid quantity and price within the specified price band, provide UPI details if applicable, and approve the mandate request before the cut-off time on the closing date. The application amount remains blocked in the bank account until the allotment process is completed.
Yes, investors are required to have an active Demat account to apply for the Q-Line Biotech IPO. Shares allotted in the IPO are credited electronically to the investor’s Demat account after the allotment process is completed. Investors are also required to have valid PAN and bank account details linked with their application.
Investors can check the allotment status through the registrar’s website or through the IPO section of their trading platform after the allotment process is completed. If shares are allotted, they will be credited to the investor’s Demat account before the tentative listing date. In case shares are not allotted, the blocked application amount is released as per the applicable process.
Disclaimer :
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading